PPARD and metabolic syndrome: In line with these observations, PPARβ/δ-null mice on a high-fat diet showed an increased rate of hepatic very-low-density lipoprotein production, and treatment of various animal models with selective PPARβ/δ agonists (GW0742 and L165041) yielded valuable data favoring PPARβ/δ as a therapeutic target for dyslipidemia [33].